



ASX ANNOUNCEMENT

18 December 2024

CARDIEX COMPLETES PLACEMENT AHEAD OF CONNEQT PULSE US LAUNCH

Not for release to US wire services or distribution in the United States

Cardiex Limited (ASX: CDX) (the **Company**) is pleased to announce the completion of a capital raising via a placement of 36,111,112 fully paid ordinary shares in the Company to institutional and sophisticated investors (the “Placement” or the “Offer”) to raise \$3.25 million (before costs).

New shares issued under the Placement will be issued at an offer price of \$0.09 per share, a 9.1% discount to the last closing price and a 9.3% discount to the 15-day VWAP. Participants in the Placement will receive one (1) free attaching listed option for every new share received under the Offer. The listed options will come under the existing class CDXOA.ASX, tradable and exercisable at \$0.20, expiring on or before 30 November 2025.

The Placement was well supported by existing institutional shareholders as well as a range of new and existing sophisticated investors from both Australia and the USA. Cardiex Directors and C2 Ventures Pty Limited, the Company’s largest shareholder that is controlled jointly by Craig Cooper, and Niall Cairns will also participate in the Placement, the issue of the shares and quoted options are subject to shareholder approval at the Company’s next general meeting.

Funds raised from the Offer will largely be used for new device manufacturing, marketing and sales activities, and for commercial expansion, including scaling up supply chain operations ahead of the January 2025 US market launch of the CONNEQT Pulse device.

New shares issued under the Placement will be issued utilising Cardiex’s existing capacity under ASX Listing Rules 7.1 and 7.1A and will rank pari passu with existing ordinary shares from the date of issue. 11,963,685 fully paid ordinary shares and 32,500,000 free attached quoted options will be issued under the Company’s Listing Rule 7.1 placement capacity, and 20,536,315 fully paid ordinary shares will be issued under the Company’s Listing Rule 7.1A placement capacity.

3,611,112 fully paid ordinary shares and 3,611,112 free attaching quoted options to be issued to the Cardiex Directors and C2 Ventures Pty Limited will be subject to shareholder approval and therefore not issued under the Company’s placement capacity.

Blackpeak Capital Pty Ltd and Stralis Capital Partners acted as Joint Lead Managers to the Placement. 6% of the total amount raised under the Placement is payable to the Joint Lead Managers.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").